Oncological Care During First Peruvian National Emergency COVID-19 Pandemic: A Multicentric Descriptive Study

Figures & data

Table 1 Clinical Characteristics (N = 1472)

Clinical Features	N (%)
Age, years
Median [Min-Max]	55 [19–97]
Age groups
<60 years	880 (59.8)
≥ 60 years	592 (40.2)
Sex
Female	959 (65.1)
Male	513 (34.9)
Cancer types
Solid tumor	1263 (85.8)
Hematologic	198 (13.5)
Others*	11 (0.7)
Clinical stage
Early	589 (44.6)
Advanced	731 (55.4)
Not reported	152
Treatment response before the pandemic
Stable or partial	709 (49.6)
In remission	423 (29.6)
Progression	297 (20.8)
Not reported	43

Note: *Others: nonmalignant neoplasms.

Abbreviations: Min, minimum; Max, maximum.

Figure 1 Participants selection process.

Table 2 Cancer Treatment Administration (N = 1472)

Variable	N (%)
Treatment delay
Yes	759 (51.6)
No	713 (48.4)
Appointment date change
Yes	626 (42.5)
No	846 (57.5)
Intravenous to oral CT switch
Yes	107 (7.3)
No	1365 (92.7)
CT discontinuation
Yes	185 (12.6)
No	1287 (87.4)
Hospital absenteeism
Yes	451 (30.6)
No	1021 (69.4)
Treatment in private center
Yes	54 (3.7)
No	1418 (96.3)

Abbreviation: CT, chemotherapy.

Table 3 Univariate and Multivariate Analysis to Death in All Patients

Analysis Type	Univariate Analysis			Multivariate Analysis
Variables	OR not adjusted	95% CI	P	OR adjusted	95% CI	p-value
Age groups
<60 years	Ref			Ref.
≥60 years	1.53	1.02–2.31	0.042	1.63	1.01–2.64	0.045
Sex
Women	Ref.			Ref.
Men	1.88	1.24–2.83	0.003	1.25	0.77–2.05	0.368
Type of cancer
Solid tumor	Ref.			Ref.
Hematological	3.14	1.98–4.97	0.001	2.50	1.34–4.69	0.004
Clinical stage
Early	Ref.			Ref.
Advanced	5.17	2.78–9.63	0.001	4.53	2.38–8.62	0.001
COVID-19 status
No	Ref.			Ref.
Yes	3.95	2.48–6.29	0.001	2.37	1.36–4.15	0.002
Appointment date change
No	Ref.			Ref.
Yes	1.51	1.00–2.27	0.05	1.08	0.66–1.77	0.758
Intravenous to oral CT switch
No	Ref.			Ref.
Yes	2.29	1.26–4.19	0.007	1.90	0.93–3.88	0.077
CT discontinuation
No	Ref.			Ref.
Yes	4.08	2.59–6.41	0.001	2.97	1.74–5.07	0.001

Abbreviation: CT, chemotherapy.

Table 4 Univariate and Multivariate Analysis to Death in COVID-19 Cases

Analysis Type	Univariate Analysis			Multivariate Analysis
Variables	OR not adjusted	95% CI	p-value	OR adjusted	95% CI	p-value
Age groups
<60 years	Ref.			Ref.
≥60 years	2.30	1.03–5.13	0.041	2.31	0.97–5.54	0.060
Cancer type
Solid tumor	Ref.			Ref.
Hematological	3.76	1.61–8.79	0.002	5.11	1.99–13.07	0.001
Treatment response
In remission	Ref.			Ref.
Stable	1.28	0.42–3.90	0.662	1.18	0.36–3.85	0.789
Progression	4.06	1.29–12.77	0.017	5.01	1.44–17.42	0.011

Table 5 Univariate and Multivariate Analysis to Death in Non-COVID-19 Cases

Analysis Type	Univariate Analysis			Multivariate Analysis
Variables	OR not adjusted	95% CI	P	OR adjusted	95% CI	p-value
Gender
Female	Ref.			Ref.
Male	1.89	1.16–3.08	0.011	1.34	0.77–2.33	0.298
Cancer type
Solid tumor	Ref.			Ref.
Hematological	2.49	1.40–4.42	0.002	2.07	0.97–4.43	0.062
Clinical stage
Early	Ref.			Ref.
Advanced	5.86	2.76–12.45	0.001	5.09	2.37–10.95	0.001
Appointment date change
No	Ref.			Ref.
Yes	2.01	1.22–3.29	0.006	1.52	0.86–2.68	0.153
Chemotherapy discontinuation
No	Ref.			Ref.
Yes	4.57	2.64–7.93	0.001	3.66	1.97–6.78	0.001